Overview and Scope
Major depressive disorder refers to a mood disorder or depression that causes a persistent feeling of sadness and loss of interest, which can interfere with daily activities such as sleeping, eating, or working. It goes beyond normal fluctuations in mood and can significantly impact a person’s thoughts, feelings, behavior and physical well-being. The treatment for major depressive disorder involves several medical interventions that support the emotional well-being of an individual
Sizing and Forecast
The major depressive disorder market size has grown steadily in recent years. It will grow from $5.96 billion in 2023 to $6.12 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to pharmaceutical advances, mental health awareness, psychological therapies, public health initiatives.
The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $6.84 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to precision medicine, telepsychiatry and teletherapy, novel treatment modalities, global expansion of mental health services. Major trends in the forecast period include early intervention, peer support and online communities, holistic approaches, resilience and coping strategies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report
Segmentation & Regional Insights
The major depressive disorder market covered in this report is segmented –
1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments
2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis
3) By End-User: Clinics; Hospitals; Other End-Users
North America was the largest region in the major depressive disorder market in 2023. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp
Major Driver Impacting Market Growth
The rise in cases of substance abuse and alcohol abuse is expected to propel the growth of the major depressive disorder market. Substance and alcohol abuse are terms used to describe patterns of excessive and harmful use of substances, including alcohol, that can lead to negative physical, psychological and social consequences. It commonly co-occurs with major depressive disorder and both conditions tend to feed off each other and significantly increase the risk of physical and mental harm. For instance, in December 2022, according to reports shared by the Office for National Statistics (ONS), a UK-based government department, in 2022, 862,000, or 2.6%, of adults between the ages of 16 and 59 reported using drugs, compared to 2.1% in 2020. Furthermore, in December 2022, according to a report published by Kirin Holdings Company Limited, a Japan-based beverage company, around 185.60 million kiloliters of beer were consumed globally in 2021, an increase of 4.0% from the year before. Therefore, the rise in cases of substance abuse and alcohol abuse is driving the growth of the major depressive disorder market.
Key Industry Players
Major players in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.
The major depressive disorder market report table of contents includes:
1. Executive Summary
2. Major Depressive Disorder Market Characteristics
3. Major Depressive Disorder Market Trends And Strategies
4. Major Depressive Disorder Market – Macro Economic Scenario
5. Global Major Depressive Disorder Market Size and Growth
.
.
.
26. South America Major Depressive Disorder Market
27. Brazil Major Depressive Disorder Market
28. Middle East Major Depressive Disorder Market
29. Africa Major Depressive Disorder Market
30. Major Depressive Disorder Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Janssen Research And Development LLC
- Merck and Co. Inc
- Novartis AG
- Sanofi-Aventis US LL
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
